GlaxoSmithKline | GSK - Frais De Vente Et D'Administration





Frais De Vente Et D'Administration Changement Date
AbbVie USD 3.58B 316M 2026-03
Alcon AG USD 882M 19M 2026-03
Amgen USD 1.58B 354M 2026-03
argenx SE USD 355M 74.62M 2026-03
AstraZeneca USD 5.06B 455M 2026-03
Bayer EUR 3.7B 356M 2026-03
Biogen USD 554.3M 128.2M 2026-03
Bristol-Myers Squibb USD 1.62B 564M 2026-03
Eli Lilly USD 2.93B 198M 2026-03
Fresenius EUR 819M 143M 2025-12
Fresenius Medical Care EUR 749M 36M 2026-03
Genmab DKK 208M 60M 2025-12
Gilead Sciences USD 1.45B 326M 2026-03
GlaxoSmithKline GBP 2.12B 558M 2026-03
Glaxosmithkline GBP 3.56B 650.29M 2025-12
GRIFOLS EUR 281M 5.7M 2026-03
Hikma Pharmaceutical USD 288M 149M 2025-12
Lakefront Biotherapeutics EUR 35.5M 8.91M 2026-03
Merck EUR 1.52B 80M 2026-03
Merck USD 2.67B 180M 2026-03
Novartis USD 3.14B 296M 2026-03
Novo Nordisk DKK 13.22B 4.22B 2026-03
Orion EUR 91.9M 18.8M 2026-03
Pfizer USD 2.92B 1.16B 2026-03
Philips EUR 1.18B 121M 2026-03
Recordati EUR 192.76M 5.52M 2026-03
Regeneron Pharmaceuticals USD 647.7M 127.3M 2026-03
Roche Holding CHF 7.28B 3.99B 2025-12
Sanofi EUR 2.33B 419M 2026-03
Smith & Nephew USD 1.42B 65M 2025-12
UCB EUR 1.47B 193M 2025-12